Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping.

ABSTRACT:

Background

The Food and Drug Administration (FDA) in the US approved primary human papillomavirus (HPV) testing for speculum-based cervical cancer screening ten years ago and, in May 2024, approved the self-collection technique. Our study defines the kappa agreement between self- and speculum-based collection techniques for 15 types of high-risk HPV. Additionally, we describe the sensitivity and specificity ratios for HPV testing using both collection methods.

Methods

Participants recruited in 2020-2022 included 97 colposcopy attendees and 96 routine primary care screening attendees aged 30-65, who agreed to self-sample before their clinically scheduled speculum-based exam. Prevalence-based kappa calculated agreement, sensitivity and specificity ratios calculated accuracy us

SUBMITTER: Young AP 

PROVIDER: S-EPMC11791345 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature